← Back to headlines
Merck Reports Positive Phase 3 Results for Oral PCSK9 Inhibitor
Merck (MRK) has announced strong Phase 3 clinical trial results for its oral PCSK9 inhibitor, a drug designed to lower cholesterol.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
